Damora Therapeutics (DMRA)
NASDAQ:DMRA
Top Page
Damora Therapeutics
(NASDAQ:DMRA)
Select Model
Select Model
Rating:56Neutral
Price Target:
$30.00
▲(22.10% Upside)
Action:ReiteratedDate:01/23/26
The score is held back primarily by weak fundamentals (no revenue, ongoing losses, and continued cash burn despite improvement) and unattractive earnings-based valuation (negative P/E). Offsetting factors include strong technical momentum (price above key moving averages with positive MACD) and positive corporate developments (Damora acquisition and associated financing extending runway).
Positive Factors
Acquisition & Financing Extends Runway
The Damora acquisition plus a $285M private placement materially lengthens funding visibility and lets Galecto advance multiple programs without immediate financing pressure. This reduces near-term dilution risk and supports multi-year clinical development timelines through key IND/POC milestones.
Negative Factors
No Revenue / Persistent Operating Losses
Galecto generates no product revenue and remains unprofitable, meaning it relies entirely on financing to fund R&D. Without commercial products, margins are absent and the path to self-sustaining cash generation depends on successful, multi-year clinical outcomes—a structural constraint.
Read all positive and negative factors
Positive Factors
Negative Factors
Acquisition & Financing Extends Runway
The Damora acquisition plus a $285M private placement materially lengthens funding visibility and lets Galecto advance multiple programs without immediate financing pressure. This reduces near-term dilution risk and supports multi-year clinical development timelines through key IND/POC milestones.
Read all positive factors
Damora Therapeutics (DMRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.48B
Dividend YieldN/A
Average Volume (3M)5.26M
Price to Earnings (P/E)―
Beta (1Y)0.25
Revenue GrowthN/A
EPS Growth37.42%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-3.24
Shares Outstanding60,303,210
10 Day Avg. Volume9,383,356
30 Day Avg. Volume5,257,093
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.57K
Enterprise Value/Ebitda-56.76
Forecast
1Y Price Target
$44.00Price Target Upside79.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.38
Revenue Forecast (FY)N/A
Damora Therapeutics Business Overview & Revenue Model
Company Description
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also inv...
How the Company Makes Money
Galecto makes money primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model hinges on advancing its pipeline of therapeutics through clinical trials, seeking regulatory approval, and ...
Damora Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -771.00K | -181.00K | -830.00K | -490.00K | -441.00K | -188.00K |
| EBITDA | -21.39M | -16.72M | -35.63M | -60.72M | -51.79M | -33.45M |
| Net Income | -25.43M | -21.44M | -38.35M | -61.62M | -51.75M | -34.84M |
Balance Sheet | ||||||
| Total Assets | 27.30M | 17.13M | 38.23M | 73.19M | 122.22M | 171.60M |
| Cash, Cash Equivalents and Short-Term Investments | 22.86M | 14.18M | 33.15M | 60.22M | 100.19M | 163.58M |
| Total Debt | 77.00K | 1.43M | 249.00K | 804.00K | 847.00K | 915.00K |
| Total Liabilities | 3.71M | 2.66M | 5.90M | 11.44M | 4.99M | 6.11M |
| Stockholders Equity | 23.59M | 14.47M | 32.33M | 61.75M | 117.22M | 165.49M |
Cash Flow | ||||||
| Free Cash Flow | -29.96M | -18.62M | -36.91M | -43.13M | -52.53M | -38.20M |
| Operating Cash Flow | -29.96M | -18.62M | -36.91M | -42.93M | -52.31M | -38.20M |
| Investing Cash Flow | 29.52M | 11.65M | 22.33M | 12.38M | -48.05M | 0.00 |
| Financing Cash Flow | 171.00K | 0.00 | 2.88M | 507.00K | 0.00 | 187.39M |
Damora Therapeutics Technical Analysis
Negative
24.57
Price Trends
26.22
Negative
25.19
Negative
14.99
Positive
Market Momentum
-0.50
Negative
47.77
Neutral
69.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DMRA, the sentiment is Negative. The current price of 24.57 is above the 20-day moving average (MA) of 24.44, below the 50-day MA of 26.22, and above the 200-day MA of 14.99, indicating a neutral trend. The MACD of -0.50 indicates Negative momentum. The RSI at 47.77 is Neutral, neither overbought nor oversold. The STOCH value of 69.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DMRA.
Damora Therapeutics Risk Analysis
Damora Therapeutics disclosed 88 risk factors in its most recent earnings report. Damora Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Damora Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.48B | -2.31 | -134.39% | ― | ― | 37.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $9.65M | ― | -334.42% | ― | ― | -228.89% | |
43 Neutral | $3.48M | -0.15 | -381.74% | ― | ― | 98.22% | |
42 Neutral | $3.52M | -0.42 | -157.24% | ― | ― | 25.19% |
* Healthcare Sector Average
DMRA
Damora Therapeutics
24.57
22.33
996.87%
MTNB
Matinas BioPharma
0.55
0.04
7.84%
QNRX
Quoin Pharmaceuticals
6.44
-0.59
-8.39%
SILO
Silo Pharma
0.36
-0.63
-64.11%
GRI
GRI Bio
2.41
-33.15
-93.22%
CDT
CDT Equity
3.95
-1,766.05
-99.78%
Damora Therapeutics Corporate Events
Business Operations and StrategyM&A TransactionsProduct-Related Announcements
Galecto Showcases New mutCALR MPN Pipeline at JPM
Positive
Jan 12, 2026
In January 2026, Galecto announced that it would present a new corporate slide deck to investors and analysts at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its recently acquired portfolio of potentially best‑in‑cla...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Galecto appoints new chief operating officer, enhances leadership
Positive
Jan 6, 2026
On December 31, 2025, Galecto issued Paramora Holding LLC a warrant to purchase up to 628,302 shares of its common stock at an exercise price of $23.01 per share, relying on a private offering exemption and adding a potential future source of equi...
Executive/Board ChangesM&A TransactionsPrivate Placements and Financing
Galecto Completes Acquisition of Damora Therapeutics
Positive
Nov 10, 2025
On November 10, 2025, Galecto, Inc. completed the acquisition of Damora Therapeutics, a biotechnology company specializing in antibody therapeutics for mutant calreticulin-driven myeloproliferative neoplasms (MPNs). This acquisition, along with a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.